NDA 205098 · Boston
Varithena
Polidocanol · Intravenous
Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Nov 25, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
42
7 Phase 3, 4 recruiting
FAERS reports
1,125
314 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 7, 2026.
VARITHENA (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. VARITHENA improves the symptoms of superficial venous incompetence and the appearance of visible varicosities. VARITHENA (polidocanol injectable foam) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. VARITHENA improves the symptoms of superficial venous incompetence and the appearance of visible varicosities. ( 1 ).
Mechanism: VARITHENA is a drug/device combination product that generates injectable foam. The injectable foam is composed of a liquid and gas phase, both of which are necessary to have its therapeutic effect. VARITHENA is intended to act as follows: (1) the foam displaces blood from the vein to be treated, and (2) the polidocanol then scleroses the endothelium. The active pharmaceutical ingredient of VARITHENA is polidocanol, a non-ionic surfactant sclerosing agent. The hydrophobic pole of the polidocanol molecule attaches to the lipid cell membrane of the venous endothelium, resulting in disruption of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 25, 2013 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewSummary Review
2 products under this application
- VARITHENA · POLIDOCANOL 180MG/18ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- VARITHENA · POLIDOCANOL 77.5MG/7.75ML (10MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Polidocanol" as an intervention, any sponsor and status, largest first.
- A Multicenter Prospective Clinical Study of Endoscopic Foam Sclerotherapy for Internal HemorrhoidsPivotal-lookingStatus unknown
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT04398823 · 700 participants (planned) · Start May 15, 2020 · Primary completion Dec 31, 2020
Drug: Sclerosing foam of Lauromacrogol; Sclersing liqiud of Lauromacrogol · For: Grade/Stage I Hemorrhoids; Prolapsed Grade II Internal Haemorrhoid; Prolapsed Grade III Internal Haemorrhoid
Sites: Shanghai, China
- Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) IncompetencePivotal-lookingCompleted
Boston Scientific CorporationIndustry
NCT01072877 · 279 participants · Start Dec 2010 · Primary completion Dec 2011
Drug: Polidocanol injectable foam (PEM); Placebo Vehicle · For: Varicose Veins
Sites: Laguna Hills, California; San Diego, California; Washington D.C., District of Columbia · 20 sites in all
- Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) IncompetencePivotal-lookingCompleted
Boston Scientific CorporationIndustry
NCT01231373 · 235 participants · Start Nov 2010 · Primary completion Sep 2011
Drug: polidocanol injectable foam, 0.125%; polidocanol injectable foam, 0.5% and 2 more · For: Varicose Veins
Sites: Dothan, Alabama; San Diego, California; Lafayette, Indiana · 12 sites in all
- Efficacy and Safety of Polidocanol Foam 3% in the Treatment of II Degree Hemorrhoidal DiseaseCompleted
Societa Italiana di Chirurgia ColoRettaleResearch network
NCT03791775 · 183 participants · Start Jan 2, 2019 · Primary completion Jun 2, 2019
Drug: Polidocanol foam (Atossisclerol® 3%) · For: Second-degree Hemorrhoids
Sites: Catanzaro, Italy
- RCT Comparing EVLA Versus Polidocanol Foam in the Treatment of SSV InsufficiencyPivotal-lookingCompleted
Societe Francaise de PhlebologieAcademic, hospital or other
NCT05468450 · 161 participants · Start Jul 1, 2015 · Primary completion Aug 31, 2016
Drug: Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant · For: Varicose Veins of Lower Limb
- ESGVS: Sclerotherapy With LauromacrogolPivotal-lookingCompleted
University Hospital, GrenobleAcademic, hospital or other
NCT00348764 · 150 participants · Start Mar 2004
Drug: lauromacrogol · For: Venous Insufficiency; Saphenous Vein
Sites: Grenoble, France
- Polidocanol Foam Versus Rubber Band Ligation in the Treatment of Hemorrhoidal DiseasePivotal-lookingCompleted
Universidade do PortoAcademic, hospital or other
NCT04091763 · 120 participants · Start Aug 1, 2018 · Primary completion Jul 1, 2020
Drug: Polidocanol Injectable Foam · For: Hemorrhoids, Internal
Sites: Porto, Portugal
- Investigation Into the Pathophysiology and Treatment of Varicose VeinsPivotal-lookingCompleted
University of SurreyAcademic, hospital or other
NCT06192472 · 120 participants · Start Apr 2013 · Primary completion Jul 2015
Drug: 1% Sodium Tetradecyl Sulphate; 3% Sodium Tetradecyl Sulphate and 2 more · For: Varicose Veins
Sites: Guildford, United Kingdom · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- deep vein thrombosis321
- no adverse event126
- off label use83
- wrong technique in product usage process78
- pain67
- product quality issue66
- pain in extremity56
- drug ineffective40
- expired product administered40
- skin discolouration39
- thrombosis38
- erythema35
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 20 |
| 2016 | 46 |
| 2017 | 73 |
| 2018 | 53 |
| 2019 | 71 |
| 2020 | 106 |
| 2021 | 195 |
| 2022 | 100 |
| 2023 | 79 |
| 2024 | 165 |
| 2025 | 96 |
| 2026 | 109 |
Recalls
1 FDA enforcement reports for this application.
Sep 7, 2016 · Class III · Terminated
Defective Delivery System: Incorrect type of syringe found in commercially distributed administration pack
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review.
Bossart S, Daneluzzi C, Cazzaniga S, et al. · J Eur Acad Dermatol Venereol 2023 · Systematic Review
- The 2022 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part I. Duplex Scanning and Treatment of Superficial Truncal Reflux: Endorsed by the Society for Vascular Medicine and the International Union of Phlebology.
Gloviczki P, Lawrence PF, Wasan SM, et al. · J Vasc Surg Venous Lymphat Disord 2023 · Meta-Analysis, Practice Guideline
- Polidocanol Sclerotherapy in Pyogenic Granulomas.
Khurana A, Mathachan SR · Dermatol Surg 2022 · Clinical Trial
- Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials.
Coombes BK, Bisset L, Vicenzino B · Lancet 2010 · Research Support, Non-U.S. Gov't, Systematic Review
- Treating telangiectasias: my method.
Ferrara F, Ferrara G · Minerva Cardioangiol 2013 · Clinical Trial
- Injection sclerotherapy for varicose veins.
Tisi PV, Beverley C, Rees A · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
Sponsor: Boston
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.